Brief: Aim Immunotech Announces That The First Subject Is Enrolled In The Phase 1B/2 Study Evaluating Ampligen® In Combination With Astrazeneca’S Imfinzi® For The Treatment Of Late-Stage Pancreatic Cancer
22/01/2024 14:16
Jan 22 (Reuters) - AIM ImmunoTech Inc AIM.A :
* AIM IMMUNOTECH ANNOUNCES THAT THE FIRST SUBJECT IS
ENROLLED IN
THE PHASE 1B/2 STUDY EVALUATING AMPLIGEN® IN COMBINATION WITH
ASTRAZENECA’S IMFINZI® FOR THE TREATMENT OF LATE-STAGE
PANCREATIC CANCER
Source text for Eikon: ID:nGNE7mnY86
Further company coverage: AIM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential